Mounjaro (Tirzepatide) SURPASS-2 Highlights infographic Video

0 SAR
Checkout

Overview

A short video to highlight the data from SURPASS-2 : Mounjaro (Tirzepatide) Vs. Semaglutide 1 mg in Type 2 diabetes.


This Class for

  • Clinical Pharmacy
  • Pharmacy
  • Physician
  • Resident / Fellow

What I will learn?

  • Shed light on the SURPASS 2 trail, A Study of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants with Type 2 Diabetes (SURPASS-2)





    Disclaimer

    This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
    (This information/content is intended to Health Care Providers only)

    For adverse events and safety reporting: email: saudi_pharmacovigilance@lilly.com
    24 /7 mobile : +966 567 868 843 working hours: +966 11 461 7800 , Ext: 1
    For Lilly product information: email: SAUDI_MEDINFOQUERIES@lilly.com
    For further information, please contact:
    Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: Saudi_Pharmacovigilance@lilly.com

    Please go to PDF Material for prescribing information


    PP-TR-SA-0054


Related Classes